Maravai LifeSciences (MRVI) Projected to Post Earnings on Tuesday

Maravai LifeSciences (NASDAQ:MRVI) is anticipated to release its earnings data after the market closes on Tuesday, February 25th. Analysts expect Maravai LifeSciences to post earnings of ($0.03) per share and revenue of $57.79 million for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Maravai LifeSciences Stock Performance

Shares of Maravai LifeSciences stock opened at $4.11 on Monday. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. The business has a 50-day moving average price of $5.06 and a two-hundred day moving average price of $6.64. Maravai LifeSciences has a 1-year low of $3.93 and a 1-year high of $11.56. The company has a market cap of $1.04 billion, a P/E ratio of -2.51 and a beta of -0.08.

Insider Buying and Selling at Maravai LifeSciences

In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of Maravai LifeSciences stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $5.03, for a total transaction of $125,750.00. Following the completion of the transaction, the general counsel now owns 167,618 shares in the company, valued at approximately $843,118.54. The trade was a 12.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.63% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on MRVI. Wolfe Research began coverage on Maravai LifeSciences in a report on Thursday, November 14th. They set a “peer perform” rating for the company. William Blair restated a “market perform” rating on shares of Maravai LifeSciences in a research note on Friday, November 8th. Robert W. Baird reduced their target price on Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. Guggenheim began coverage on Maravai LifeSciences in a research note on Thursday, December 19th. They issued a “neutral” rating for the company. Finally, Royal Bank of Canada reduced their target price on Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $10.32.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.